Work

Phase I trials of the oral histone deacetylase (HDAC) inhibitor MGCD0103 given either daily or 3x weekly for 14 days every 3 weeks in patients (pts) with advanced solid tumors

Year: 2005

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2005.23.16_suppl.3147

Authors: K. Gelmon, A. Tolcher, M. Carducci, G. K. Reid, Z. Li, A. Kalita, V. Callejas, J. Longstreth, J. M. Besterman, L. L. Siu

Institutions: BC Cancer Agency, Princess Margaret Cancer Centre, Vancouver Clinic

Language: English

Topic: Histone Deacetylase Inhibitors Research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2265866827

Cites:

Cited by: 18

Related to: 10